Seegene’s solution for the new VOC, Omicron

2021.11. 29 | Global Marketing Center

REPRESENTANTE EXCLUSIVO EN CHILE

Copyrightⓒ Seegene Inc., All Rights Reserved [ Confidential | Seegene Inc. Global Marketing Center ]
New COVID-19 threat, Omicron variant
The newest COVID-19 variant, Omicron, has been designated as VOC
Properties of Omicron
34 of mutations in S gene, and a number of changes and deletions in other genes*;

Omicron Gene Mutation

S A67V, Δ69-70**, T95I, G142D, Δ143-145, Δ211, L212I, ins214EPE,
PANGO B.1.1.529 G339D, S371L, S373P, S375F, K417N**, N440K, G446S, S477N,
T478K, E484A, Q493K, G496S, Q498R, N501Y**, Y505H, T547K,
GISAID GR/484A D614G, H655Y, N679K, P681H**, N764K, D796Y, N856K, Q954H,
N969K, L981F
First report to WHO Nov 24, 2021 (S. Africa) E T9I
N P13L, Δ31- 33, R203K, G204R
Status of spreading†
11 Nov in Botswana and on M D3G, Q19E, A63T
14 Nov in South Africa NSP3 K38R, V1069I, Δ1265, L1266I, A1892T
26 Nov in Belgium, Hong Kong and Israel
NSP4 T492I
29 Nov in Austria, Australia, Canada, Italy, and UK
NSP5 P132H
† https://www.gisaid.org/hcov19-variants/
NSP6 Δ105-107, A189V
NSP12 P323L
NSP14 I42V
* Reference; ECDC, 26 November 2021
** Detectable with Allplex SARS-CoV-2 Master Assay and Allplex SARS-CoV-2 Variants I / II Assay
Global Status of Omicron spreading
Tracking of Variants (As of 29 Nov 2021)

https://www.gisaid.org/hcov19-variants/
SG’s solution to detect the new variant, Omicron
AllplexTM SARS-CoV-2 Master Assay covers the new VOC, Omicron

Omicron’s spike Symptomatic/Suspected

mutations
patient

A67V, Δ69-70*,
T95I, G142D,
Δ143-145, Δ211,
L212I, ins214EPE,
G339D, S371L,
S373P, S375F,
K417N*, N440K,
G446S, S477N,
T478K, E484A, N501Y*
Q493K, G496S, HV69/70 del*
Q498R, N501Y*,
Y505H, T547K, P681H* + E, RdRP/S, N gene
+ E, RdRP/S, N gene
D614G, H655Y, E484K - S variants
+ S variants
N679K, P681H*,
N764K, D796Y, Y144del
N856K, Q954H, *Mutation found in Omicron Variant
N969K, L981F
Omicron Delta…
So far, Delta variants are dominant globally.
Frequency pattern change: From Alpha to Delta variant
In countries which perform sequencing analysis, Delta variant is dominant
As of 15 NoV 2021 As of 29 NoV 2021 As of 15 NoV 2021 As of 29 NoV 2021
Botswana Omicron, 3 South Africa Omicron, 7 Israel Belgium

As of 29 NoV 2021 As of 29 NoV 2021 As of 15 NoV 2021 As of 18 Oct 2021

Italy Germany Spain South Korea

https://covariants.org/per-country

Recently, alpha, beta, and gamma variants have not been reported
 Thank you
2021.11. 29 |

Copyrightⓒ Seegene Inc., All Rights Reserved [ Confidential | Seegene Inc. Global Marketing Center ]
No worry about the new variant, Omicron, with Seegene’s SARS-CoV-2 portfolio Appendix

Based on the in-silico analysis,

ALL Seegene’s SARS-CoV-2 assays using multiple targets are able to detect the new worry, Omicron variant

Note.
In the case of Allplex SARS-CoV-2/FluA/FluB/RSV assay,
there is a chance to observe a delayed Ct or drop out of certain gene due to a mismatch

Detectable Percentage (%)*

Seegene Assay
E gene RdRP gene S gene N gene
AllplexTM 2019-nCoV Assay (Cat# RP10244Y/10243X) 100.0 100.0 Non-target 100.0

AllplexTM SARS-CoV-2 Assay (Cat# RV10247T/10248X) 100.0 100.0 100.0

AllplexTM SARS-CoV-2/FluA/FluB/RSV Assay (Cat# RV10260Y/10259X) Non-target 100.0 100.0 85.7**

* In-silico analysis by Omicron sequence (As of 27 Nov 2021)
** Due to limited sequence number; coverage information to be updated
SG’s solution to distinguish the new variant, Omicron Appendix
AllplexTM SARS-CoV-2 Variant I & II Assay can distinguish Omicron and Others such as α, β, and Υ

SARS-CoV-2 Positive
patient

Assay Allplex SARS-CoV-2 Variants I Allplex SARS-CoV-2 Variants II

Predicted Results
Variant HV69/70del* E484K N501Y* W152C L452R K417N* K417T
Omicron
POS - POS - - POS - HV 69/70 del, N501Y, K417N
(B.1.1.529)
α
POS - POS - - - - HV 69/70 del, N501Y
(B.1.1.7)
β
- POS POS - - POS - E484K, N501Y, K417N
(B.1.351)
Υ
- POS POS - - - POS E484K, N501Y, K417T
(P.1)
Delta
- - - - POS - - L452R
(B.1.617.2)
*Mutation found in Omicron Variant
Whitepaper of SG’s Variants Assay Appendix
1. AllplexTM SARS-CoV-2 Master Assay

2. AllplexTM SARS-CoV-2 Variants I Assay

3. AllplexTM SARS-CoV-2 Variants II Assay